Evotec stock: November 5, 2026 results date puts Evotec stock on the calendar

Published on 10/19/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit EUR 465.00 million in nine months on October 13, 2026. Evotec stock costs EUR 2.62 on October 19, 2026, up 1.95 percent versus Xetra close.

Dates and operating figures

Evotec will publish full third-quarter and nine-month results on November 5, 2026.
For the first nine months of 2026, revenue was EUR 465.00 million.
Evotec stock costs EUR 2.62 at Lang & Schwarz on October 19, 2026 at 4:32 p.m. CEST, 1.95 percent above the Xetra close of October 16, 2026.
Evotec's market capitalization was EUR 463.9 million on October 19, 2026.

Schwarzweiß-Dokumentarfoto einer Forscherin am Mikroskop in einem biotechnologischen Labor — Schwarzweiß-Reportagefoto zeigt Laborarbeit im Biotech-Sektor, passend zu Evotec SE, ISIN DE0005664809, dokumentarischer Forschungsalltag, Illustration mit AI erstellt.

Evotec (DE0005664809) has its full third-quarter and nine-month results scheduled for November 5, 2026, according to Investing.com. The calendar date follows preliminary nine-month revenue of EUR 465.00 million and adjusted EBITDA of minus EUR 42.80 million reported on October 13, 2026. At 4:32 p.m. CEST, the stock was trading at EUR 2.62 at Lang & Schwarz, up 1.95 percent versus the Xetra close of October 16, 2026 at EUR 2.57.

Nine-month figures set the baseline

Evotec's preliminary revenue for the first nine months of 2026 stood at EUR 465.00 million. The adjusted EBITDA result was minus EUR 42.80 million, while full-year guidance remained at EUR 570.00 million to EUR 610.00 million of revenue and adjusted EBITDA of minus EUR 70.00 million to minus EUR 105.00 million.

Investing.com reported that the figures exceeded current market expectations, but also said the difference mainly reflected the timing of consensus estimates. That distinction keeps the November report important for judging the underlying operating trend.

Stock stays near its yearly low

The 52-week range is EUR 2.41 to EUR 7.30 as of October 19, 2026. The Lang & Schwarz price is 8.71 percent above the low and 64.11 percent below the high, leaving the stock much closer to the lower end of its annual range.

The latest intraday quote from the Xetra listing was EUR 2.61 at 4:24 p.m. CEST, with a daily range of EUR 2.50 to EUR 2.61. Evotec's market capitalization was EUR 463.9 million, and its price-to-earnings ratio was minus 2.36 on October 19, 2026.

Comparison with peers

Evotec (Xetra, EUR): plus 1.95 percent, P/E minus 2.36, market capitalization EUR 463.9 million

Sartorius (Xetra, EUR): plus 0.46 percent, P/E 92.51, market capitalization EUR 16.2 billion

Qiagen (Xetra, EUR): plus 0.49 percent, P/E 23.58, market capitalization EUR 8.5 billion

Trading price and next date

The November 5, 2026 reporting date gives investors a clear calendar marker. Evotec's preliminary figures provide the operating baseline, while the price remains 1.95 percent above the October 16 Xetra close and below the upper half of its 52-week range. The stock was trading at EUR 2.62 at Lang & Schwarz on October 19, 2026 at 4:32 p.m. CEST, plus 1.95 percent versus the Xetra close of October 16, 2026 at EUR 2.57. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.